Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative bioavailability study of immediate-release and sustained-release flucytosine formulations in healthy adults
PACTR202201760181404Phase 1Completed
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of flucytosine in invasive mycoses (4 arms), sponsored by Drugs for Neglected Diseases initiative. Primary endpoint: Relative bioavailability. Started Jan 2022; status: completed.
02
Drugs
flucytosine
03
Conditions
invasive mycoses
Beyond the preview
Go deeper on PACTR202201760181404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202201760181404.